Analysts had forecast a blockbuster year for life science mergers and acquisitions as the lower tax rate for repatriated cash kicks-in and Big Pharma continues its hunt for late-stage assets.
{iframe}https://medcitynews.com/2018/01/anatomy-two-biotech-deals-worth-20b/?utm_campaign=MCN%20Daily%20Top%20Stories&utm_source=hs_email&utm_medium=email&utm_content=60154561&_hsenc=p2ANqtz-8PELItGR-LuafbyKTAX63Y7tMOWz3wuqzXai53xOL98QsyMCDpsnD2eH8vIOeWzdQX5AKZPPr3Gsr2mSMEjLmL7fKNsQ&_hsmi=60154561{/iframe}